A trial to compare the serum levels of the bio-chemical bone resorption marker CTX-I after antiresorptive drug administration such as zoledronic acid or denosumab.

Trial Profile

A trial to compare the serum levels of the bio-chemical bone resorption marker CTX-I after antiresorptive drug administration such as zoledronic acid or denosumab.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2016

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 May 2016 New trial record
    • 17 Apr 2016 Results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top